VNRX · Volitionrx Ltd - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $985.1K | - | $627.3K | $406.7K | $246.4K | - | $474.5K | $395.8K | $171.5K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $2.85M | - | $2.29M | $2.72M | $2.61M | - | $3.47M | $3.72M | $4.63M | - |
| SG&A | $2.63M | - | $2.48M | $2.94M | $2.24M | - | $1.82M | $2.28M | $2.25M | - |
| Total Operating Expenses | $6.33M | - | $5.73M | $6.70M | $5.77M | - | $6.34M | $7.39M | $8.56M | - |
| D&A | $207.4K | - | - | - | $251.9K | - | - | - | $263.2K | - |
| Operating Income | ($5.35M) | - | ($5.10M) | ($6.30M) | ($5.52M) | - | ($5.87M) | ($6.99M) | ($8.38M) | - |
| Interest Expense | $125.8K | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($6.66M) | - | ($5.38M) | ($6.28M) | ($5.42M) | - | ($5.87M) | ($7.06M) | ($8.47M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.97) | - | ($1.40) | ($1.60) | ($2.00) | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.10M | $1.12M | $200.0K | $2.30M | $2.60M | $3.26M | $5.41M | $6.00M | $11.77M | $20.73M |
| Accounts Receivable | $252.2K | $317.8K | $309.1K | $189.6K | $187.8K | $110.6K | $312.6K | $166.3K | $133.5K | $242.6K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.72M | $2.92M | $3.11M | $2.35M | $3.01M | $2.77M | $2.49M | $3.35M | $3.53M | $3.21M |
| Current Assets | $4.52M | $2.06M | $1.33M | $3.26M | $3.29M | $4.06M | $6.80M | $7.35M | $13.47M | $21.85M |
| Total Assets | $9.04M | $6.90M | $6.45M | $8.70M | $8.52M | $9.40M | $12.68M | $13.07M | $19.43M | $27.95M |
| Current Liabilities | $13.57M | $12.23M | $11.42M | $9.24M | $8.27M | $7.79M | $30.28M | $30.98M | $31.49M | $31.84M |
| Long-term Debt | $6.35M | $5.82M | $5.57M | $5.77M | $5.53M | $3.95M | $3.84M | $3.87M | $3.37M | $3.62M |
| Total Liabilities | $42.40M | $42.49M | $42.40M | $41.80M | $37.55M | $35.51M | $35.32M | $35.97M | $36.05M | $36.66M |
| Stockholders' Equity | ($31.97M) | ($34.25M) | ($34.64M) | ($31.82M) | ($27.77M) | ($24.91M) | ($21.50M) | ($21.81M) | ($15.61M) | ($7.80M) |
| Retained Earnings | ($259.57M) | ($252.90M) | ($246.63M) | ($241.25M) | ($234.97M) | ($229.54M) | ($223.75M) | ($217.93M) | ($210.94M) | ($202.58M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($5.28M) | - | - | - | ($4.30M) | - | - | - | ($8.34M) | - |
| Investing Cash Flow | ($9.2K) | - | - | - | ($1.8K) | - | - | - | ($78.8K) | - |
| Financing Cash Flow | $7.62M | - | - | - | $3.67M | - | - | - | ($209.4K) | - |
| CapEx | $9.2K | - | - | - | $1.8K | - | - | - | $28.8K | - |
| Free Cash Flow | ($5.29M) | - | - | - | ($4.30M) | - | - | - | ($8.37M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -543.0% | - | -813.2% | -1548.6% | -2241.1% | - | -1236.8% | -1766.2% | -4887.9% | - |
| EBITDA margin | -521.9% | - | - | - | -2138.8% | - | - | - | -4734.5% | - |
| Net margin | -676.6% | - | -857.4% | -1545.2% | -2201.3% | - | -1236.7% | -1783.8% | -4938.9% | - |
| Free cash flow margin | -536.9% | - | - | - | -1745.2% | - | - | - | -4880.2% | - |
| FCF / Net income | 0.79 | - | - | - | 0.79 | - | - | - | 0.99 | - |
| R&D / Revenue | 289.5% | - | 364.4% | 668.9% | 1058.3% | - | 732.1% | 938.8% | 2698.9% | - |
| SG&A / Revenue | 267.0% | - | 396.0% | 723.1% | 910.5% | - | 382.7% | 577.1% | 1313.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -73.8% | - | -83.4% | -72.2% | -63.7% | - | -46.3% | -54.0% | -43.6% | - |
| Return on equity | 20.8% | - | 15.5% | 19.8% | 19.5% | - | 27.3% | 32.4% | 54.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.33 | 0.17 | 0.12 | 0.35 | 0.40 | 0.52 | 0.22 | 0.24 | 0.43 | 0.69 |
| Quick ratio | 0.33 | 0.17 | 0.12 | 0.35 | 0.40 | 0.52 | 0.22 | 0.24 | 0.43 | 0.69 |
| Cash ratio | 0.23 | 0.09 | 0.02 | 0.25 | 0.31 | 0.42 | 0.18 | 0.19 | 0.37 | 0.65 |
| Leverage | ||||||||||
| Debt / Equity | -0.20 | -0.17 | -0.16 | -0.18 | -0.20 | -0.16 | -0.18 | -0.18 | -0.22 | -0.46 |
| Debt / Assets | 0.70 | 0.84 | 0.86 | 0.66 | 0.65 | 0.42 | 0.30 | 0.30 | 0.17 | 0.13 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -42.5x | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -0.28 | -0.20 | -0.19 | -0.27 | -0.31 | -0.38 | -0.59 | -0.60 | -1.25 | -3.58 |
| Liabilities / Assets | 4.69 | 6.16 | 6.57 | 4.80 | 4.41 | 3.78 | 2.79 | 2.75 | 1.86 | 1.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.10 | 0.05 | 0.03 | - | 0.04 | 0.03 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 93d | - | 180d | 170d | 278d | - | 240d | 153d | 284d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 27.9x | - | 1905.5x | 3089.8x | 3792.1x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 299.8% | - | 32.2% | 2.8% | 43.6% | - | 187.2% | 83.0% | 14.5% | - |
| Revenue CAGR (3y) | 87.3% | - | 167.7% | 117.1% | 29.2% | - | 165.1% | 151.8% | 88.7% | - |
| Revenue CAGR (5y) | 107.6% | - | 305.1% | - | 239.8% | - | 94.4% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 3.1% | - | 13.1% | 9.9% | 34.1% | - | 32.2% | 26.8% | 7.3% | - |
| Net income growth (YoY) | -22.9% | - | 8.4% | 11.0% | 36.0% | - | 30.6% | 26.1% | 3.5% | - |
| EPS growth (YoY) | 51.5% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -23.0% | - | - | - | 48.6% | - | - | - | 6.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -15.1% | -37.5% | -61.1% | -45.9% | -78.0% | -219.2% | -952.7% | - | -568.1% | -149.5% |
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing VOLITIONRX LTD against the 5 most active filers in the same SIC group.